GRAL

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

Wall Street analysts forecast GRAL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRAL is 60.86 USD with a low forecast of 38.00 USD and a high forecast of 83.71 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Grail Inc revenue for the last quarter amounts to 36.19M USD, increased 26.32 % YoY.

Grail Inc. EPS for the last quarter amounts to -2.46 USD, decreased -37.56 % YoY.

Grail Inc (GRAL) has 1000 emplpoyees as of December 15 2025.

Today GRAL has the market capitalization of 3.54B USD.